Do clinical trial results predict real-world outcomes for patients with diabetic macular edema or neovascular age-related macular degeneration who receive second-generation retinal therapies? Real-world factors to consider include more diverse patients, less-controlled practice conditions, and variability in treatment patterns and durability. This interactive, match game style CME activity compares second generation retinal therapies across efficacy, safety, and durability, helping ophthalmologists reconcile clinical trial data with real-world findings to optimize outcomes in routine practice where formal guidance is limited.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJun 30, 2026
-
Last day to claim creditJul 1, 2027 9 months left
-
Paradigm Medical Communications, LLC Beyond the Clinical Trials: The Real-World Impact of Second-Generation Therapy
-
Paradigm Medical Communications, LLC Imaging-Based Retinal Decision-Making in the Era of Second-Generation Therapy
-
Paradigm Medical Communications, LLC Moving Beyond Misconceptions: The Reality of Sustained Delivery Therapies in Retina Practice
